Detalhe da pesquisa
1.
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology.
Brain
; 145(3): 1001-1017, 2022 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285474
2.
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.
Neurobiol Dis
; 162: 105579, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871735
3.
Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
Biochem Soc Trans
; 50(1): 621-632, 2022 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35225340
4.
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation.
Brain
; 144(5): 1509-1525, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876242
5.
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Neurobiol Dis
; 159: 105487, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34419621
6.
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Neurobiol Dis
; 144: 105044, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32798726
7.
NOP Receptor Ligands and Parkinson's Disease.
Handb Exp Pharmacol
; 254: 213-232, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30689087
8.
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
Neurobiol Dis
; 120: 21-33, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30172844
9.
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Neurobiol Dis
; 118: 1-8, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29908325
10.
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4.
J Neuroinflammation
; 15(1): 297, 2018 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30368241
11.
Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.
J Pharmacol Exp Ther
; 364(2): 198-206, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29167350
12.
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
Neurobiol Dis
; 85: 155-163, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26522958
13.
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
Neurobiol Dis
; 89: 55-64, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26804029
14.
Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
J Neurosci
; 34(39): 12953-62, 2014 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25253844
15.
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Mov Disord
; 30(13): 1728-38, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26207892
16.
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease.
Analyst
; 140(11): 3830-9, 2015 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25584655
17.
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.
Neurobiol Dis
; 71: 62-73, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25107341
18.
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
J Neurosci
; 32(46): 16106-19, 2012 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23152595
19.
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Brain
; 135(Pt 6): 1884-99, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22561640
20.
Modeling Parkinson's disease in LRRK2 rodents.
Neuronal Signal
; 7(3): NS20220040, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37601008